For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Emergent Biosolutions Inc (NYSE: EBS) was $11.72 for the day, up 1.38% from the previous closing price of $11.56. In other words, the price has increased by $1.38 from its previous closing price. On the day, 0.65 million shares were traded. EBS stock price reached its highest trading level at $11.8 during the session, while it also had its lowest trading level at $11.46.
Ratios:
Our analysis of EBS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.47 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 439.67. For the most recent quarter (mrq), Quick Ratio is recorded 3.15 and its Current Ratio is at 5.76. In the meantime, Its Debt-to-Equity ratio is 1.15 whereas as Long-Term Debt/Eq ratio is at 1.15.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $15. On August 22, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $16. The Benchmark Company Upgraded its Hold to Buy on March 07, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 05 ’25 when Richard Ronald sold 21,984 shares for $11.97 per share. The transaction valued at 263,077 led to the insider holds 98,417 shares of the business.
RONALD RICHARD bought 32,848 shares of EBS for $392,335 on Dec 05 ’25. On Nov 10 ’25, another insider, DeGolyer Donald W, who serves as the Director of the company, sold 17,801 shares for $10.54 each. As a result, the insider received 187,623 and left with 119,858 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EBS now has a Market Capitalization of 625274880 and an Enterprise Value of 1041033984. As of this moment, Emergent’s Price-to-Earnings (P/E) ratio for their current fiscal year is 9.06. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.78 while its Price-to-Book (P/B) ratio in mrq is 1.06. Its current Enterprise Value per Revenue stands at 1.32 whereas that against EBITDA is 4.732.
Stock Price History:
The Beta on a monthly basis for EBS is 2.32, which has changed by 0.38207543 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, EBS has reached a high of $13.41, while it has fallen to a 52-week low of $4.02. The 50-Day Moving Average of the stock is 13.44%, while the 200-Day Moving Average is calculated to be 55.06%.
Shares Statistics:
EBS traded an average of 1.08M shares per day over the past three months and 823690 shares per day over the past ten days. A total of 52.70M shares are outstanding, with a floating share count of 50.44M. Insiders hold about 3.95% of the company’s shares, while institutions hold 79.63% stake in the company. Shares short for EBS as of 1764288000 were 8917402 with a Short Ratio of 8.23, compared to 1761868800 on 8220839. Therefore, it implies a Short% of Shares Outstanding of 8917402 and a Short% of Float of 17.16.
Earnings Estimates
A detailed examination of Emergent Biosolutions Inc (EBS) is currently in progress, with 1.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.97, with high estimates of $0.97 and low estimates of $0.97.
Analysts are recommending an EPS of between $2.05 and $2.05 for the fiscal current year, implying an average EPS of $2.05. EPS for the following year is $4.02, with 1.0 analysts recommending between $4.02 and $4.02.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 2 analysts. It ranges from a high estimate of $220M to a low estimate of $215M. As of. The current estimate, Emergent Biosolutions Inc’s year-ago sales were $194.7MFor the next quarter, 2 analysts are estimating revenue of $275M. There is a high estimate of $275M for the next quarter, whereas the lowest estimate is $275M.
A total of 2 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $809.6M, while the lowest revenue estimate was $809.2M, resulting in an average revenue estimate of $809.4M. In the same quarter a year ago, actual revenue was $1.04BBased on 1 analysts’ estimates, the company’s revenue will be $1.16B in the next fiscal year. The high estimate is $1.16B and the low estimate is $1.16B.
